1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,780 | 5,100 | 14:24 |
► 14.05.: | | | | | |
15:00 |
16:00 |
17:00 |
17:30
► 13.05.: | | | | | | | | |
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
► 13.05.: | | | | | | | | |
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 22,200 | 30 | |||
| 20,000 | 83 | |||
| 16,000 | 532 | |||
| 15,000 | 15 | |||
| 5,100 | 953 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 953 | 4,780 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.014 | 0,804 | 1.619 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:06 | 4basebio Plc - Appointment of Chief Financial Officer and Board Changes | 229 | PR Newswire | 4basebio Plc - Appointment of Chief Financial Officer and Board Changes
PR Newswire
LONDON, United Kingdom, May 14
4basebio... ► Artikel lesen | |
| Di | IN BRIEF: 4basebio launches high-capacity single-stranded DNA platform | 9 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Mo | 4basebio Launches Enzymatic ssDNA Platform | 16 | GlobeNewswire (USA) | ||
| Mo | 4basebio Plc - 4basebio Launches Enzymatic ssDNA Platform | 305 | PR Newswire | 4basebio Plc - 4basebio Launches Enzymatic ssDNA Platform
PR Newswire
LONDON, United Kingdom, May 11
4basebio... ► Artikel lesen | |
| 01.04. | 4BaseBio expands facilities to support growing synthetic DNA demand | 37 | Alliance News |
1 2 3 4 5 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:38 | OS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor | Newsfile | Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation... ► Artikel lesen | |
| 13:16 | XFRA RB0: AUSSETZUNG/SUSPENSION | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREGENXBIO INC. DL-... ► Artikel lesen | |
| 13:36 | Celcuity Inc.: Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients | GlobeNewswire (Europe) | MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid... ► Artikel lesen | |
| 13:36 | CorMedix, Inc.: Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | GlobeNewswire (Europe) | ? Q1 2026 Net Revenue of $127.4 million ? ? Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ? - Company raises FY 2026 Revenue and Adjusted EBITDA Guidance - ? Conference Call... ► Artikel lesen | |
| 14:02 | MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 | ACCESS Newswire | Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 4BASEBIO PLC finden Sie auf Wallstreet Online.